Talk:Sugammadex: Difference between revisions
No edit summary |
|||
Line 3: | Line 3: | ||
==Phase III data== |
==Phase III data== |
||
Any preliminary phase 3 data available for sharing? [[User:Mdw346|Mdw346]] 15:33, 7 December 2006 (UTC)MDW 07 Dec.06 |
Any preliminary phase 3 data available for sharing? [[User:Mdw346|Mdw346]] 15:33, 7 December 2006 (UTC)MDW 07 Dec.06 |
||
Sept 16, 2007: |
|||
Preliminary Phase III and updated Phase II data has been released in Europe June 9-12, 2007 at the European Society of Anaesthesiology Munich, Germany. No surprises- continued successful, effective, dose-dependent fast time to reversal of all levels of neuromuscular blockade induced by rocuronium and vecuronium. Shallow level blockade induced by pancuronium was effectively conducted by Decoopman M, et al. Referenced in "sugammade" wiki article. Pediatric, elderly, cardiac disease, pulmonary disease, and renal disease patients also successfully treated with sugammadex (ESA mtg. June 2007. ASA mtg. October 2007). Concerns of QTc prolongation by sugammadex addressed by de Kam PJ, et al (Single IV sugammadex doses up to 32 mg/kg are not associated with QT/QTc prolongation. Anesthesiology 2007;107:A1580)The authors concluded sugammadex did not prolong the QT interval based on ICH-E14 guideline criteria. |
Preliminary Phase III and updated Phase II data has been released in Europe June 9-12, 2007 at the European Society of Anaesthesiology Munich, Germany. No surprises- continued successful, effective, dose-dependent fast time to reversal of all levels of neuromuscular blockade induced by rocuronium and vecuronium. Shallow level blockade induced by pancuronium was effectively conducted by Decoopman M, et al. Referenced in "sugammade" wiki article. Pediatric, elderly, cardiac disease, pulmonary disease, and renal disease patients also successfully treated with sugammadex (ESA mtg. June 2007. ASA mtg. October 2007). Concerns of QTc prolongation by sugammadex addressed by de Kam PJ, et al (Single IV sugammadex doses up to 32 mg/kg are not associated with QT/QTc prolongation. Anesthesiology 2007;107:A1580)The authors concluded sugammadex did not prolong the QT interval based on ICH-E14 guideline criteria. |
Revision as of 12:01, 16 September 2007
![]() | Pharmacology Start‑class | |||||||||
|
Phase III data
Any preliminary phase 3 data available for sharing? Mdw346 15:33, 7 December 2006 (UTC)MDW 07 Dec.06
Sept 16, 2007: Preliminary Phase III and updated Phase II data has been released in Europe June 9-12, 2007 at the European Society of Anaesthesiology Munich, Germany. No surprises- continued successful, effective, dose-dependent fast time to reversal of all levels of neuromuscular blockade induced by rocuronium and vecuronium. Shallow level blockade induced by pancuronium was effectively conducted by Decoopman M, et al. Referenced in "sugammade" wiki article. Pediatric, elderly, cardiac disease, pulmonary disease, and renal disease patients also successfully treated with sugammadex (ESA mtg. June 2007. ASA mtg. October 2007). Concerns of QTc prolongation by sugammadex addressed by de Kam PJ, et al (Single IV sugammadex doses up to 32 mg/kg are not associated with QT/QTc prolongation. Anesthesiology 2007;107:A1580)The authors concluded sugammadex did not prolong the QT interval based on ICH-E14 guideline criteria.